These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

483 related items for PubMed ID: 24722560

  • 1. Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial.
    Abbas Z, Yakoob J, Jafri W, Ahmad Z, Azam Z, Usman MW, Shamim S, Islam M.
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):630-9. PubMed ID: 24722560
    [Abstract] [Full Text] [Related]

  • 2. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life.
    Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ.
    J Clin Gastroenterol; 2011 Sep; 45(8):679-83. PubMed ID: 21301358
    [Abstract] [Full Text] [Related]

  • 3. Role of Saccharomyces boulardii in diarrhea predominant irritable bowel syndrome.
    Kabir MA, Ishaque SM, Ali MS, Mahmuduzzaman M, Hasan M.
    Mymensingh Med J; 2011 Jul; 20(3):397-401. PubMed ID: 21804501
    [Abstract] [Full Text] [Related]

  • 4. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS, Seo JG.
    J Clin Gastroenterol; 2012 Mar; 46(3):220-7. PubMed ID: 22157240
    [Abstract] [Full Text] [Related]

  • 5. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii.
    Bafutto M, Almeida JR, Leite NV, Costa MB, Oliveira EC, Resende-Filho J.
    Arq Gastroenterol; 2013 Mar; 50(4):304-9. PubMed ID: 24474234
    [Abstract] [Full Text] [Related]

  • 6. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome.
    Ishaque SM, Khosruzzaman SM, Ahmed DS, Sah MP.
    BMC Gastroenterol; 2018 May 25; 18(1):71. PubMed ID: 29801486
    [Abstract] [Full Text] [Related]

  • 7. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome.
    Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P.
    Gastroenterol Clin Biol; 2008 Feb 25; 32(2):147-52. PubMed ID: 18387426
    [Abstract] [Full Text] [Related]

  • 8. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome.
    Dolin BJ.
    Methods Find Exp Clin Pharmacol; 2009 Dec 25; 31(10):655-9. PubMed ID: 20140275
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study.
    Cindoruk M, Erkan G, Karakan T, Dursun A, Unal S.
    Helicobacter; 2007 Aug 25; 12(4):309-16. PubMed ID: 17669103
    [Abstract] [Full Text] [Related]

  • 10. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial.
    Pozzoni P, Riva A, Bellatorre AG, Amigoni M, Redaelli E, Ronchetti A, Stefani M, Tironi R, Molteni EE, Conte D, Casazza G, Colli A.
    Am J Gastroenterol; 2012 Jun 25; 107(6):922-31. PubMed ID: 22472744
    [Abstract] [Full Text] [Related]

  • 11. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study.
    Guglielmetti S, Mora D, Gschwender M, Popp K.
    Aliment Pharmacol Ther; 2011 May 25; 33(10):1123-32. PubMed ID: 21418261
    [Abstract] [Full Text] [Related]

  • 12. Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome--a pilot study.
    Tuteja AK, Fang JC, Al-Suqi M, Stoddard GJ, Hale DC.
    Scand J Gastroenterol; 2012 Oct 25; 47(10):1159-64. PubMed ID: 22783919
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of Probiotic Escherichia coli Nissle 1917 in Patients with Irritable Bowel Syndrome: a Double Blind Placebo-controlled Randomized Trial.
    Faghihi AH, Agah S, Masoudi M, Ghafoori SM, Eshraghi A.
    Acta Med Indones; 2015 Jul 25; 47(3):201-8. PubMed ID: 26586385
    [Abstract] [Full Text] [Related]

  • 14. A randomized double-blind placebo-controlled clinical trial on efficacy and safety of association of simethicone and Bacillus coagulans (Colinox®) in patients with irritable bowel syndrome.
    Urgesi R, Casale C, Pistelli R, Rapaccini GL, de Vitis I.
    Eur Rev Med Pharmacol Sci; 2014 Jul 25; 18(9):1344-53. PubMed ID: 24867512
    [Abstract] [Full Text] [Related]

  • 15. Clinical trial: transcutaneous interferential electrical stimulation in individuals with irritable bowel syndrome - a prospective double-blind randomized study.
    Coban Ş, Akbal E, Köklü S, Köklü G, Ulaşlı MA, Erkeç S, Aktaş B, Yüksel O, Koçak E, Erdem HR.
    Digestion; 2012 Jul 25; 86(2):86-93. PubMed ID: 22846190
    [Abstract] [Full Text] [Related]

  • 16. The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study.
    Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H, Majsiak E, Bierła JB, Kanarek E, Sowińska A, Cukrowska B.
    Nutrients; 2021 Feb 26; 13(3):. PubMed ID: 33652763
    [Abstract] [Full Text] [Related]

  • 17. The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Sun YY, Li M, Li YY, Li LX, Zhai WZ, Wang P, Yang XX, Gu X, Song LJ, Li Z, Zuo XL, Li YQ.
    Sci Rep; 2018 Feb 14; 8(1):2964. PubMed ID: 29445178
    [Abstract] [Full Text] [Related]

  • 18. Prescript-Assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study.
    Bittner AC, Croffut RM, Stranahan MC.
    Clin Ther; 2005 Jun 14; 27(6):755-61. PubMed ID: 16117982
    [Abstract] [Full Text] [Related]

  • 19. Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS.
    Brun P, Scarpa M, Marchiori C, Sarasin G, Caputi V, Porzionato A, Giron MC, Palù G, Castagliuolo I.
    PLoS One; 2017 Jun 14; 12(7):e0181863. PubMed ID: 28732069
    [Abstract] [Full Text] [Related]

  • 20. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life.
    Lorenzo-Zúñiga V, Llop E, Suárez C, Alvarez B, Abreu L, Espadaler J, Serra J.
    World J Gastroenterol; 2014 Jul 14; 20(26):8709-16. PubMed ID: 25024629
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.